Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

aducanumab-avwa

- PMLiVE

New UK research institute launched for motor neurone disease

The research institute will bring together MND labs, clinical centres and researchers

- PMLiVE

Alzheimer’s Research UK survey highlights dementia knowledge gaps

The UK poll revealed that only 60% of adults know that dementia is a cause of death

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation

Eisai said it aims to apply for US approval of SC Leqembi by the end of March 2024

- PMLiVE

Alzheimer’s Society raises concerns over undiagnosed young-onset dementia cases

The UK charity estimates that over 19,000 people in England are living without a diagnosis

- PMLiVE

UCL study finds certain ethnicities experience greater effect of dementia risk factors

Researchers analysed health data from nearly one million adults in England

- PMLiVE

New Swedish study finds HSCT can slow progression of multiple sclerosis

More than 70% of participants in the study had no new progression after five years of treatment

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

Biogen Idec building

Biogen’s Actemra biosimilar approved by FDA to treat adult and paediatric arthritis

Tofidence is now the first biosimilar referencing Actemra to gain approval from the US regulator

- PMLiVE

Alzheimer’s Research UK launches ‘Change The Ending’ campaign

A survey revealed that 22% of 2,162 people were unaware of the impact dementia has on people’s everyday lives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links